文献速递糖尿病肥胖与代谢综合征

2型糖尿病多基因评分在土著研究人群中用于预测2型糖尿病发病率的效用:出生、青年和成人队列研究

The utility of a type 2 diabetes polygenic score in addition to clinical variables for prediction of type 2 diabetes incidence in birth, youth and adult cohorts in an Indigenous study population.
PubMed 文献 · Diabetologia · 2023-03-02

在美国西南部土著人群中,分析十种2型糖尿病多基因评分(PS)构建方式,并在成人、青年和出生三个基线无糖尿病的队列中评估PS联合临床变量对2型糖尿病发病的预测价值。基于欧洲 ancestry 人群293个全基因组显著变异的PS表现最佳,在三个队列中均显著提升预测,AUC分别从0.728升至0.735、0.805升至0.812、0.614升至0.685,NRI分别为0.270、0.268和0.362。

要点

  • 基于欧洲人群293个变异的PS在三个队列中均与2型糖尿病发病显著相关(HR 1.27-1.49每SD)。
  • PS的预测区分能力与HbA1c等常用临床变量相似,在较严格干预阈值下净获益更明显。

核心结论

  • 本研究表明,欧洲来源的PS在美国西南部土著研究人群中,除临床变量信息外,对预测2型糖尿病发病有显著贡献。
  • PS的区分能力与其它常用临床变量(如HbA1c)相似。
  • 在临床变量之外加入2型糖尿病PS,可能对识别高风险个体具有临床益处,尤其是在较年轻年龄段。

研究设计与样本

  • 研究为纵向研究,对象为美国西南部一个2型糖尿病高患病率的土著人群。
  • 分析十种基于公开全基因组关联研究(GWAS)汇总统计的PS构建方式。
  • 在三个基线无糖尿病的队列中检查2型糖尿病发病率:成人队列2333人(从≥20岁随访,640例发病)、青年队列2229人(从5-19岁随访,228例发病)、出生队列2894人(从出生随访,438例发病)。

主要发现

  • 十种PS构建中,使用欧洲 ancestry 人群大型2型糖尿病GWAS荟萃分析中293个全基因组显著变异的PS表现最佳。
  • 成人队列中,仅临床变量预测2型糖尿病发病的AUC为0.728,加入PS后为0.735;PS的HR为每SD 1.27(p=1.6×10-8;95%CI 1.17,1.38)。
  • 青年队列中,对应AUC为0.805和0.812;PS的HR为1.49(p=4.3×10-8;95%CI 1.29,1.72)。
  • 出生队列中,AUC为0.614和0.685;PS的HR为1.48(p=2.8×10-16;95%CI 1.35,1.63)。
  • PS的净重分类改善(NRI)在成人、青年和出生队列分别为0.270、0.268和0.362;作为比较,HbA1c的NRI在成人队列为0.267,在青年队列为0.173。

关键数值与推荐

  • 在决策曲线分析中,所有队列中在临床变量之外加入PS的净获益,在启动预防性干预的中等严格阈值概率值处最为明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: There is limited information on how polygenic scores (PSs), based on variants from genome-wide association studies (GWASs) of type 2 diabetes, add to clinical variables in predicting type 2 diabetes incidence, particularly in non-European-ancestry populations. METHODS: For participants in a longitudinal study in an Indigenous population from the Southwestern USA with high type 2 diabetes prevalence, we analysed ten constructions of PS using publicly available GWAS summary statistics. Type 2 diabetes incidence was examined in three cohorts of individuals without diabetes at baseline. The adult cohort, 2333 participants followed from age ≥20 years, had 640 type 2 diabetes cases. The youth cohort included 2229 participants followed from age 5-19 years (228 cases). The birth cohort included 2894 participants followed from birth (438 cases). We assessed contributions of PSs and clinical variables in predicting type 2 diabetes incidence. RESULTS: Of the ten PS constructions, a PS using 293 genome-wide significant variants from a large type 2 diabetes GWAS meta-analysis in European-ancestry populations performed best. In the adult cohort, the AUC of the receiver operating characteristic curve for clinical variables for prediction of incident type 2 diabetes was 0.728; with the PS, 0.735. The PS's HR was 1.27 per SD (p=1.6 × 10-8; 95% CI 1.17, 1.38). In youth, corresponding AUCs were 0.805 and 0.812, with HR 1.49 (p=4.3 × 10-8; 95% CI 1.29, 1.72). In the birth cohort, AUCs were 0.614 and 0.685, with HR 1.48 (p=2.8 × 10-16; 95% CI 1.35, 1.63). To further assess the potential impact of including PS for assessing individual risk, net reclassification improvement (NRI) was calculated: NRI for the PS was 0.270, 0.268 and 0.362 for adult, youth and birth cohorts, respectively. For comparison, NRI for HbA1c was 0.267 and 0.173 for adult and youth cohorts, respectively. In decision curve analyses across all cohorts, the net benefit of including the PS in addition to clinical variables was most pronounced at moderately stringent threshold probability values for instituting a preventive intervention. CONCLUSIONS/INTERPRETATION: This study demonstrates that a European-derived PS contributes significantly to prediction of type 2 diabetes incidence in addition to information provided by clinical variables in this Indigenous study population. Discriminatory power of the PS was similar to that of other commonly measured clinical variables (e.g. HbA1c). Including type 2 diabetes PS in addition to clinical variables may be clinically beneficial for identifying individuals at higher risk for the disease, especially at younger ages.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Wedekind LE, Mahajan A, Hsueh WC, et al. The utility of a type 2 diabetes polygenic score in addition to clinical variables for prediction of type 2 diabetes incidence in birth, youth and adult cohorts in an Indigenous study population. Diabetologia. 2023. PMID: 36862161. doi:10.1007/s00125-023-05870-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。